Overcoming resistance of targeted EGFR monotherapy by inhibition of STAT3 escape pathway in soft tissue sarcoma

Although epidermal growth factor receptor (EGFR) is often over-expressed in soft tissue sarcoma (STS), a phase II trial using an EGFR inhibitor gefitinib showed a low response rate. This study identified a new secondary resistance mechanism of gefitinib in STS, and developed new strategies to improv...

Celý popis

Uloženo v:
Podrobná bibliografie
Vydáno v:Oncotarget
Hlavní autoři: Wang, Xiaochun, Goldstein, David, Crowe, Philip J., Yang, Mark, Garrett, Kerryn, Zeps, Nikolajs, Yang, Jia-Lin
Médium: Artigo
Jazyk:Inglês
Vydáno: Impact Journals LLC 2016
Témata:
Research Paper
On-line přístup:https://ncbi.nlm.nih.gov/pmc/articles/PMC5008301/
https://ncbi.nlm.nih.gov/pubmed/26909593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/oncotarget.7452
Tagy: Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!

Podobné jednotky